ReviewESMO open2020
Precision oncology in urothelial cancer.
Review in ESMO open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Treatment strategies for cisplatin-ineligible metastatic bladder cancer: Emerging therapies and future perspectives.Investigative and clinical urology · 2025Review
- Germline whole-exome sequencing revealsJournal for immunotherapy of cancer · 2025Article
- Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical Applications.Biomedicines · 2025Review
- The Use of Artificial Intelligence in Urologic Oncology: Current Insights and Challenges.Research and reports in urology · 2025Review
- Article
- The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care.BJUI compass · 2024Review
- Existing trends and applications of artificial intelligence in urothelial cancer A scoping review.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Article
- [Molecular diagnostics of bladder cancer-practical ramifications].Der Urologe. Ausg. A · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genomics-driven, precision medicine has been adopted in virtually every tumour type and underlies the significant advances in cancer management to date. The paradigm shift from the indiscriminate use of chemotherapeutics, to strategies that harness our mechanistic knowledge of cancer biology has led to profound clinical benefit for patients, and will continue to mould present and future treatment approaches. In the realm of urothelial cancer, the present status of precision medicine includes a rich landscape that encompasses molecularly-matched therapy, predictive biomarkers that could help inform response to chemotherapy and immunotherapy, as well as novel strategies such as antibody drug conjugates that exploit the use of target proteins for enhanced tumour killing. Here, we present an overview on these clinically-impactful discoveries in urothelial cancer, discuss the limitations and challenges in the implementation of precision oncology, and offer our vision for its future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.